美中嘉和公告，控股股东北京泰和诚于2025年6月20日通过大宗交易出售3280万股公司H股，每股价格 为6.12港元，占公司已发行股份总数的约4.46%。董事会预计此次减持不会对公司的业务经营造成不利 影响。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 內幕消息 本公司控股股東減持股份 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公 司，「本集團」））根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市 規則」）第13.09條以及根據證券及期貨條例（香港法例第571章）第XIVA部所訂明 的內幕消息條文（定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）獲本公司控股股東（定義見香港聯合交易所有 限公司證券上市規則）之一北京泰和誠醫療技術有限公司（「北京泰和誠」）告知， 北京泰和誠於2025年6月20日通過大宗交易出售合共32,800,000股本公司H股，每 股價格為6.12港元，佔本公司於本公告日期已發行股份總數的約4.46%（「出 ...

Summary of Proton and Heavy Ion Therapy Industry Conference Call Industry Overview - The National Health Commission has relaxed licensing for proton and heavy ion therapy, benefiting private hospitals [2][3] - Approximately 53 licenses for proton and heavy ion therapy have been issued in China, but the number of operational centers remains low compared to Europe and the US [3][7] - The latest policy allows non-public hospitals to apply for licenses, which is favorable for private hospitals [3] Key Company Insights - Guangzhou Taikang Cancer Hospital's proton center has been operational since late 2024, treating nearly 200 patients with a single treatment costing 295,000 RMB [2][4] - The hospital's outpatient volume is close to 1,000 visits, indicating strong initial performance [4] - Revenue from proton and heavy ion therapy is approximately 60 million RMB year-to-date, but actual financial income may vary due to settlement cycles with self-pay and commercial insurance patients [5][11] - Shanghai Taihe Cancer Hospital is expected to open in 2026, with its proton center operational by 2027-2028, involving a total investment of 3 billion RMB [8] Financial Performance - The overall revenue of Guangzhou Taikang Cancer Hospital is stable compared to the previous year, with further data on other services pending [6] - The hospital aims to treat 1,000 patients in 2025, which could significantly reduce losses, although net profit may still be challenging to achieve due to high initial investments [10] Market Dynamics - The treatment is not covered by health insurance, with commercial insurance accounting for about 10%-20% of payments, which is expected to increase in the future [11] - The competitive landscape in Shanghai is robust, with the first proton center operating at full capacity, treating around 1,000 patients annually [7] Technological Developments - The company has developed an AI model for proton therapy, currently deployed in Guangzhou, with plans to expand its application to other treatment areas [14][15] - The trend in radiation therapy is moving towards more precise methods, with proton and heavy ion therapies being among the most advanced [12] Future Outlook - The company is focused on optimizing operations in its three hospitals before exploring external growth opportunities [17] - The proportion of revenue from radiation therapy exceeds 50%, highlighting its significance in the company's overall business model [18] - Pricing for proton therapy is expected to remain stable in the short term due to limited competition, but may adjust in the long term as more centers open [19] Regulatory and Competitive Landscape - The company is monitoring the impact of national healthcare price reforms on future gross margins, particularly in the context of service price reductions [13] - Domestic manufacturers are gradually improving their technology, with potential for local production to reduce treatment costs [19]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告不會於美國或其境內直接或間接分發。本公告並不構成或組成於美國購買或認購證券之 任何要約或招攬之一部分。本公告所述之本公司股份並未亦將不會根據1933年美國證券法（經 修訂）（「證券法」）登記，且除非已根據證券法之登記規定登記或獲豁免登記，否則將不得於美 國提呈發售或出售。本公司股份將不會於美國公開發售。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453) 完成根據一般授權配售新股份 獨家整體協調人、配售代理及資本市場中介人 茲提述美中嘉和醫學技術發展集團股份有限公司（「本公司」）日期為2025年5月29 日的公告，內容有關根據一般授權配售18,600,000股新H股（「配售公告」）。除另 有所指外，本公告所用詞 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) 公司名稱： 美中嘉和醫學技術發展集團股份有限公司 呈交日期： 2025年6月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | ...

Company Overview - Meizhong Jiahe Medical Technology Development Group Co., Ltd. is a leading comprehensive oncology medical solution platform in China, focusing on advanced oncology diagnosis and treatment technology research, development, transformation, and application [4] - The company has attracted significant strategic investments from well-known institutions such as CICC Capital, CITIC Xingye, and Shenshan Asset, positioning itself as a mixed-ownership enterprise to promote the development and transformation of medical services in China [4] - Meizhong Jiahe operates multiple international oncology specialty medical institutions across major cities in China, ranking second among private oncology medical groups in terms of the number of owned medical institutions [4] Financial Performance - As of December 31, 2024, Meizhong Jiahe reported total operating revenue of 388 million yuan, a year-on-year decrease of 27.91%, and a net profit attributable to shareholders of -443 million yuan, a year-on-year decrease of 18.8% [2] - The company's gross margin stands at -17.32%, with a debt-to-asset ratio of 67.82% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Meizhong Jiahe's stock [3] - The company's price-to-earnings (P/E) ratio is -9.38, ranking 76th in the healthcare equipment and services industry, which has an average P/E ratio of -20.22 [3] Business Model and Services - Meizhong Jiahe provides comprehensive oncology medical services, including diagnosis and treatment solutions, operational management, equipment leasing, and maintenance services [4] - The company has developed a cloud-based business model to empower enterprise clients, particularly in lower-tier cities, through remote consultation, quality control, supply chain management, and joint research [4][5] - The company has launched platforms such as "Jiahe Cloud Imaging Remote Medical Information Diagnosis Platform" and "Jiahe Feiyun Intelligent Radiotherapy Cloud Platform" to enhance the quality of oncology diagnosis and treatment in underserved areas [4] Technological Advancements - Meizhong Jiahe has strong technical capabilities in radiation therapy, having hosted the first guideline project approved by the National Cancer Center's Radiation Quality Control Expert Committee led by a private medical institution [5] - The company has received approval for additional guidelines related to radiation therapy data auditing and remote treatment planning, further solidifying its expertise in the field [5]

Group 1: Market Overview - The report indicates that the US court's ruling against imposing comprehensive tariffs has led to market optimism regarding the end of the trade war, resulting in a rise in US stock markets and a halt to the five-day decline in A-shares [2][3] - The Hang Seng Index opened lower but rebounded significantly, closing up 315 points or 1.4%, with notable increases in major blue-chip stocks such as Meituan, Alibaba, and JD.com [3] Group 2: Macroeconomic and Industry Dynamics - The Financial Secretary of Hong Kong, Paul Chan, expressed intentions to strengthen ties with the Middle East market, highlighting the potential for collaboration in various financial products, including bonds and derivatives, following the listing of the first Saudi Islamic bond ETF in Hong Kong [6] - The CEO of Hong Kong Exchanges and Clearing, Charles Li, noted the growing momentum for connectivity between Hong Kong and Middle Eastern markets, with significant cooperation already established across various sectors [7] Group 3: Company News - New World Development is in the process of securing an HKD 87.5 billion refinancing deal, which has garnered significant attention from Hong Kong bankers, with at least 12 banks agreeing to terms so far [10] - CSPC Pharmaceutical Group reported a year-on-year decrease of 8.36% in net profit for the first quarter, with total revenue down 21.91%, primarily due to the impact of government policies on drug pricing [11] - Meizhong Pharmaceutical announced a placement of 18.6 million new H-shares at a discount of 19.7% to raise HKD 100 million for various operational needs [12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告不會於美國或其境內直接或間接分發。本公告並不構成或組成於美國購買或認購證券之 任何要約或招攬之一部分。本公告所述之本公司股份並未亦將不會根據1933年美國證券法（經 修訂）（「證券法」）登記，且除非已根據證券法之登記規定登記或獲豁免登記，否則將不得於美 國提呈發售或出售。本公司股份將不會於美國公開發售。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 根據一般授權按配售協議配售新股份 獨家整體協調人、配售代理及資本市場中介人 於2025年5月28日（交易時段後），本公司與配售代理訂立配售協議。據此，配 售代理已有條件同意擔任本公司獨家配售代理，並以盡最大努力基準促使不少 於六(6)名承配人（該等承配人及其最 ...

Core Insights - The article highlights the significant breakthrough of Meizhong Jiahe (02453.HK) in the field of tumor precision diagnosis and treatment, particularly with the launch of its self-developed proton therapy vertical large language model [1][4] - The deployment of this model at Guangzhou Taihe Tumor Hospital marks a milestone in the intelligentization of tumor medical services, showcasing the company's strong technical capabilities and immense commercial potential [1][4] Company Developments - Meizhong Jiahe's subsidiary, Beijing Hexin Kang Technology Co., Ltd., established in 2015, focuses on improving medical services through artificial intelligence technology [1] - The proton large model is a pioneering achievement in the proton therapy vertical field, establishing industry technical standards and filling a gap in the market [1][3] Application and Impact - The proton large model has been successfully implemented at Guangzhou Taihe Tumor Hospital, which is the first clinical center in South China equipped with the Varian ProBeam proton radiation therapy system [2] - The model's training data is sourced from the hospital's clinical processes, ensuring accuracy and relevance, which enhances the efficiency of "human-machine collaboration" in treatment [2] Future Plans - The development plan for the proton large model extends beyond proton therapy, aiming to create an AI diagnostic matrix covering the entire lifecycle of tumor screening, diagnosis, treatment, and rehabilitation [3] - This approach allows Meizhong Jiahe to improve the efficiency and quality of its medical services while also enabling diverse collaborations with other medical institutions through technology licensing and remote diagnostic support [3] Market Position - As the first company in Hong Kong to engage in proton therapy, Meizhong Jiahe has established a strong competitive barrier in the tumor diagnosis and treatment sector [4] - The launch of the proton large model elevates the company's advantages, redefining industry standards and accelerating the intelligent transformation of the tumor medical industry [4]

美中嘉和醫學技術發展集團股份有限公司 CONCORD HEALTHCARE GROUP CO., LTD. （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 董事名單及其角色與職能 李雪梅女士 孫延生先生 吳國賢先生 1 董事會已成立審核委員會、薪酬與考核委員會及提名委員會，該等委員會由以下 成員組成： | | 董事委員會 | 審計委員會 | 薪酬與考核委員 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | 會 | | | 楊建宇博士 | | | M | M | | 付驍女士 | | | | | | 常亮先生 | | | | | | 王雷先生 | | | | | | 宋清寶先生 | | | | | | 施波濤先生 | | | | | | 李雪梅女士 | | M | C | M | | 孫延生先生 | | M | M | C | | 吳國賢先生 | | C | | | 美中嘉和醫學技術發展集團股份有限公司董事會（「董事會」）成員載列如下： 執行董事 楊建宇博士 （董事長） 付驍女士 常亮先生 非執行董事 王雷先生 宋清寶先生 施波濤先生 ...